Lakefront Biotherapeutics American Depositary Shares
LKFT
82 hedge funds and large institutions have $720M invested in Lakefront Biotherapeutics American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 19 closing their positions.
15% more call options, than puts
Call options by funds: $18.2M | Put options by funds: $15.8M
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0.09% more ownership
Funds ownership: 19.54% → 19.64% (+0.09%)
9% less funds holding
Funds holding: 90 → 82 (-8)
9% less capital invested
Capital invested by funds: $793M → $720M (-$73.3M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$83.1M |
| 2 |
Jennison Associates
New York
|
+$17.9M |
| 3 |
Optiver Holding
Amsterdam,
Netherlands
|
+$17.8M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$15.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$64.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31.6M |
| 3 |
6CM
683 Capital Management
New York
|
-$20.7M |
| 4 |
Millennium Management
New York
|
-$17.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$13.3M |
LKFT Hedge Fund Activity: Q2 2022 in Review
82 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2022, worth a combined $720M — down 9.2% from $793M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LKFT and 12 opened new positions — a net loss of 7 holders — while 26 trimmed existing stakes and 28 added.
The largest buyer was Fidelity Investments, adding an estimated $83.1M. The largest seller was BVF Inc, exiting entirely with an estimated $64.9M sold.
- 82 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2022, down from 90 in Q1 2022.
- Funds reported $720M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2022, down 9.2% quarter-over-quarter.
- 12 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2022 and 19 closed out, a net change of -7 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2022 was Fidelity Investments, an estimated $83.1M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2022 was BVF Inc, an estimated $64.9M sold.
Based on aggregated 13F filings for Q2 2022.